Taking tamoxifen for ten years following breast cancer surgery rather than five is more effective and better at reducing the risk of recurrence and death, according to a recent trial led by Oxford University's Clinical Trial Service Unit (CTSU), called ATLAS. The findings, published online in...
New research led by the University of Manchester in the UK has found a biomarker or molecular "flag" in women with breast cancer who do not repond, or who have become resistant, to treatment with the hormone drug tamoxifen. The researchers say their discovery will help doctors predict which...
Cancer researchers at the Kimmel Cancer Center at Jefferson and an international team of collaborators have discovered a biomarker in breast cancer that may help identify which women will respond to anti-estrogen therapy. The research appears in the May 16 online issue of the Journal of...
SCIENTISTS in London have found a potential new way of boosting the effectiveness of the anti-breast cancer drug, tamoxifen. The work carried out by Professor Clare Isacke and her team at the Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research (ICR), and partly funded...
Gene could predict tamoxifen treatment failure Scientists in Belfast have identified a gene which could predict whether women with breast cancer will respond to treatment with tamoxifen, according to findings published today in Cancer Research. Dr Tracy Robson and researcher Dr Hayley McKeen...
Gene could predict tamoxifen treatment failure Scientists in Belfast have identified a gene which could predict whether women with breast cancer will respond to treatment with tamoxifen, according to findings published today in Cancer Research. Dr Tracy Robson and researcher Dr Hayley McKeen...